Abstract

Temporally precise inhibition of distinct cell types in the intact nervous system has been enabled by the microbial halorhodopsin NpHR, a fast light-activated electrogenic Cl− pump. While neurons can be optically hyperpolarized and inhibited from firing action potentials at moderate NpHR expression levels, we have encountered challenges with pushing expression to extremely high levels, including apparent intracellular accumulations. We therefore sought to molecularly engineer NpHR to achieve strong expression without these cellular side effects. We found that high expression correlated with endoplasmic reticulum (ER) accumulation, and that under these conditions NpHR colocalized with ER proteins containing the KDEL ER retention sequence. We screened a number of different putative modulators of membrane trafficking and identified a combination of two motifs, an N-terminal signal peptide and a C-terminal ER export sequence, that markedly promoted membrane localization and ER export defined by confocal microscopy and whole-cell patch clamp. The modified NpHR displayed increased peak photocurrent in the absence of aggregations or toxicity, and potent optical inhibition was observed not only in vitro but also in vivo with thalamic single-unit recording. The new enhanced NpHR (eNpHR) allows safe, high-level expression in mammalian neurons, without toxicity and with augmented inhibitory function, in vitro and in vivo.

Technical challenges still remain, including refining optical and cell type-specific targeting strategies, as well as tuning activation wavelengths and ion permeabilities for different classes of experiments. One major challenge in adapting tools across large evolutionary distances (e.g., to mammals from prokaryotes and simple eukaryotes such as Volvox carteri, Natronomonas pharaonis, and Chlamydomonas reinhardtii) is that expressing heterologous membrane proteins in mammalian cells can lead to poor folding, assembly, and trafficking. We have previously reported that at high expression levels, NpHR (codon optimized for mammalian expression) forms aggregates that could cause cellular toxicity (Gradinaru et al., 2007), and noted that this problem could be alleviated by returning to moderate expression levels, but this was not an ideal solution because large photocurrents are useful for efficient inhibition in a variety of experiments, especially for in vivo applications. Therefore, we report here on a strategy to increase the efficiency of NpHR membrane targeting to maximize photocurrents without aggregations or toxicity, even for high expression levels under strong promoters, in vitro and in vivo.

Results

In order to reduce the incidence of intracellular aggregates observed with NpHR at high expression levels, we first attempted to regulate distribution of the NpHR protein within the cell by using signal peptides from either ChR2 (Nagel et al., 2003) or the α and β subunits of the nicotinic acetylcholine receptor (nAChR; Isenberg and Meyer, 1989; Bocquet et al., 2007), PDZ binding motifs (Zito et al., 1999; Weick et al., 2003; Guerrero et al., 2005), and actin binding motifs (Petrecca et al., 2000) (Fig. 1A). Although for most of the NpHR variants this strategy considerably reduced the number of cells with aggregates while maintaining photocurrents (Fig. 1B, C), aggregates were still observed and when present were as large as with wild-type NpHR. Next, after extensive analysis of the formation, distribution, and evolution of the NpHR aggregates in cultured neurons (data not shown) we observed that the localization of the aggregates appeared similar to ER localization in the soma and dendrites. Indeed, immunocytochemistry confirmed that NpHR aggregates colocalized with proteins containing the KDEL signal for ER retention (Fig. 2B, top row), while NpHR itself does not contain a KDEL motif or other known ER retention signals (e.g., the KKAA- or RSRR-class signals).

Protein aggregation and photocurrents altered by changes in intracellular targeting of NpHR. (A) Table of screened intracellular targeting strategies using N- and C-terminal peptides fused to NpHR. (B) The fraction of neurons containing one or more NpHR aggregates was determined in cultured hippocampal neurons transduced with quantitatively titer-matched viral CaMKIIα::NpHR-EYFP constructs, and allowed to express for 10 days. Compared to the unmodified NpHR (orange), some constructs (gray) had little effect on aggregates while others (blue) partially reduced aggregate incidence. Notably, for one construct (*) aggregates and toxicity were virtually abolished (only a single possible aggregate observed in >400 neurons). Data shown are relative to wild-type NpHR, and the number of neurons sampled for each construct is shown in parenthesis after the construct label. (C) Functionality was assessed by whole-cell patch clamp (for details see “Methods” and Fig. 3B). All the constructs were functional as indicated by photocurrents that were comparable to the original NpHR, but one construct, the optimal construct from (B) (*), gave rise to significantly higher photocurrent per cell than all other variants (eNpHR). Data shown are relative to wild-type NpHR, and the number of neurons sampled for each construct is shown in parenthesis after the construct label

Intracellular targeting of eNpHR. (A) Primary structure of the selected construct (eNpHR) showing addition of the N-terminal signal peptide derived from nAChR and the C-terminal ER export signal derived from Kir2.1. Expression here was driven by the CaMKIIα promoter and visualized by fusion to EYFP. (B) Top row: Untargeted NpHR (green) colocalized with somatic ER (KDEL ER protein staining in red; overlap indicated in yellow and by arrows) and also notably aggregated in ER-rich regions of the dendrites (overlap indicated in yellow and by arrowheads). Bottom row: Little colocalization of eNpHR with somatic ER staining could be found, and indeed pronounced accumulations of ER staining in eNpHR dendrites were not observed. Right column: representative images of neuronal populations expressing NpHR and eNpHR. The neurons were infected with quantitatively titer-matched CaMKIIα-NpHR-EYFP or CaMKIIα-eNpHR-EYFP

Transport along the secretory pathway, with ER export being the first step in the pathway, is crucial for surface expression of integral membrane proteins. Although some proteins can exit the ER by bulk flow, ER export of membrane proteins can be impaired if the protein is either misfolded or lacks specific export signals (Li et al., 2000; Ellgaard and Helenius, 2003). Because NpHR is functional in mammalian neurons even in vivo (Zhang et al., 2007a) we hypothesized that aggregate formation might be due to lack of an ER export signal rather than frank misfolding, and therefore sought to determine if adding different ER export signals to the NpHR sequence would abolish aggregate formation. C-terminal ER export signals have been shown to be important for efficient processing and surface expression of many membrane proteins (Farhan et al., 2008). Additionally, previous work has found that when the C-terminal ER export signals on Kv1.4 (VXXSL) or Kir2.1 (FCYENEV) are either mutated or deleted, the resulting protein forms large spheroidal intracellular accumulations similar to NpHR aggregates, and corresponding channel activity is reduced due to lower protein levels in the plasma membrane (Levitan and Takimoto, 2000; Ma et al., 2001; Stockklausner et al., 2001). Moreover, suggesting that functionality can be transferred solely with these motifs, the FCYENEV sequence accelerated surface expression and increased current levels for the lobster shal potassium channel (Kv4) when added to the C-terminus (Zhang and Harris-Warrick, 2004). Indeed, in the course of our modification screen we found that adding FCYENEV to the NpHR C-terminus along with the signal peptide from the β subunit of the nAChR to the NpHR N-terminus prevented aggregate formation (Fig. 1B, asterisk), with such markedly improved properties that we named the resulting tool eNpHR (enhanced NpHR; Fig. 2A) and studied its behavior further (summarized in Figs. 2–4).

First, we found that in contrast to NpHR, eNpHR did not colocalize with ER proteins (Fig. 2B), or show evidence of toxicity even at high expression levels. eNpHR appeared to be present in somatic Golgi structures, typical for transmembrane proteins as they are packaged for transport (Ma et al., 2001; Horton and Ehlers, 2003; Hofherr et al., 2005). Notably, eNpHR showed more surface membrane localization as defined by whole-cell photocurrents (Fig. 3). Indeed, presumably due to increased export from the ER and increased membrane localization, eNpHR displayed significantly higher photocurrents compared to NpHR in cultured neurons infected with quantitatively titer-matched virus levels and allowed to express for the same amount of time (Fig. 3: NpHR: 38.9 ± 6.8 pA; eNpHR 68.1 ± 7.2 pA; mean ± SEM; unpaired t-test P = 0.008), while membrane resistance was indistinguishable in the two groups (NpHR: 113.5 ± 13.9 mΩ; eNpHR: 116.8 ± 13.9 mΩ; unpaired t-test P = 0.87).

To assess eNpHR function in the setting of high in vivo expression levels, we injected highly concentrated and quantitatively titer-matched virus for both NpHR and eNpHR under the strong CaMKIIα promoter into the CA1 region of adult mouse hippocampus. While NpHR showed aggregates after 10 days of expression in vivo, eNpHR did not show any aggregates or affect cellular integrity, confirming the tolerability and improved targeting of the engineered protein even at these very high expression levels (Fig. 4A, top row); enhanced membrane localization of eNpHR in vivo was also evident in dendrites (Fig. 4A, bottom row). To confirm functionality, we conducted in vivo recordings using a combined optical fiber/electrode “optrode” previously described (Gradinaru et al., 2007), and found that activity of single units in adult mouse thalamus expressing eNpHR (Fig. 4B, confocal image) could be readily and reversibly inhibited with yellow light (Fig. 4B, middle) in vivo; no such effect was seen in non-transduced tissue (Fig. 4B, bottom).

In vivo function of eNpHR at high expression level. (A) Confocal images showing NpHR and eNpHR expression in rodent hippocampal CA1. NpHR aggregations were clearly visualized after 10 days of strong expression of high titer virus (left) while eNpHR showed no signs of aggregates or toxicity (right) with quantitatively matched viral titers (see “Methods”). Lower panels: magnified views of the dendritic layer. Compared to NpHR, eNpHR revealed not only absence of aggregates but also more membrane localization in distal processes in vivo. (B) Simultaneous optical stimulation and electrophysiology in living mice demonstrates eNpHR potency in vivo: single unit recordings in deep brain structures. Yellow illumination delivered by the optrode method (Gradinaru et al., 2007) in vivo inhibited electrical activity in thalamus previously transduced with eNpHR by lentiviral stereotactic injection (middle trace). Top trace: same thalamic region, recording without illumination. Bottom trace: control recording 1 mm ventral and anterior from the eNpHR injection site. As expected, in non-transduced tissue, light did not inhibit recorded spikes. Confocal image: eNpHR expression in the thalamus (same animal). Inset: expanded view of a spike from unit (*) represented in the top trace

Discussion

In this study we have identified and corrected a major limiting factor in the application of optogenetic inhibition (complementary results have been obtained with our colleagues at Duke University; Zhao et al., 2008). We traced the problem associated with high NpHR expression back to a membrane trafficking complication (Figs. 1 and 2), tested a large number of possible solutions (Fig. 1), and validated the efficacy of the best strategy both in vitro (Figs. 1–3) and in vivo (Fig. 4). We found that eNpHR completely abolished accumulations seen at very high expression levels with the original NpHR, apparently in part by allowing normal export of NpHR from the ER (assessed by confocal imaging) and by driving increased surface membrane expression (validated by quantified photocurrents). At this point we recommend use of eNpHR for all applications, and certainly those involving high expression levels in mammalian neurons, including transgenic mouse line generation (Zhao et al., 2008) and viral transduction approaches. We also anticipate that these modifications may enhance the expression of other microbial opsins at high levels and over long durations, pointing to the likely utility of generating similarly enhanced versions of ChR2 and VChR1.

The altered properties of eNpHR as described here clearly do not simply represent a subtle quantitative change in performance, but rather a distinct step in the development of this optogenetic technology. Future improvements could incrementally further advance eNpHR function, perhaps including the Golgi export signals from Kir2.1 (Stockklausner and Klocker, 2003; Hofherr et al., 2005), subcellular localization motifs (as in Gradinaru et al., 2007), and mutations that shift wavelength dependence, kinetics, light sensitivity, and ion selectivity. For example, blueshifting ChR2 and redshifting eNpHR and VChR1 will improve the ease with which combinatorial experiments are conducted, and a roadmap for the key residues likely to be involved and the type of changes likely to be helpful in this regard has been described (Zhang et al., 2008).

Finally, it has been noted (Zhang et al., 2008) that VChR1 and ChR2 (representing yellow light excitation and blue light excitation, respectively) when used together will allow combinatorial tests of the importance of specific activity patterns in interacting cell types. For example, a principal cell population can be recruited with VChR1/yellow light, in the presence or absence of precisely patterned activity in a candidate modulatory cell type driven by added blue light/ChR2. Combinatorial experiments are important to consider now for eNpHR as well, given its improved functionality in vitro and in vivo. For example, coexpression of eNpHR and ChR2 in the same cell type could allow testing the necessity and sufficiency of that specific cell type in neural circuit or animal behavior. Moreover, epistatic relationships among different cell groups within a neuronal network could be probed by expressing eNpHR and ChR2 in different cell types and determining if the functional significance of cell population A excitation is expressed through or “read out” via a candidate downstream cell population B; this hypothesis could be tested by reversibly inhibiting cell population B (yellow light/eNpHR) in the presence of population A activation (blue light/ChR2). In this way the causal neural codes underlying circuit computation and behavior may be slowly assembled, moving toward the long term goal of understanding how neural system properties emerge from component dynamics, both in health and disease.

Methods

DNA constructs

All NpHR variants were produced by PCR amplification of the NpHR-EYFP construct previously published (Zhang et al., 2007a) and cloned in-frame into the AgeI and EcoRI restriction sites of a lentivirus carrying the CaMKIIα promoter according to standard molecular biology protocols. All constructs were fully sequenced to check for accuracy of the cloning procedure. The map for eNpHR is available online at http://www.optogenetics.org.

Lentivirus preparation and titering

Lentiviruses for cultured neuron infection and for in vivo injection were produced as previously described (Zhang et al., 2007a). Viral titering was performed in HEK293 cells that were grown in 24-well plates and inoculated with 5-fold serial dilutions in the presence of polybrene (8 μg/μl). After 4 days, cultures were resuspended in PBS and sorted for EYFP fluorescence on a FACScan flow cytometer (collecting 20,000 events per sample) followed by analysis using FlowJo software (Ashland, OR). The titer of the virus was determined as follows: [(% of infected cells) × (total number of cells in well) × (dilution factor)]/(volume of inoculum added to cells) = infectious units/ml. The titer of viruses for culture infection was 105 i.u./ml. The titer of concentrated virus for in vivo injection was 1010 i.u./ml.

Immunostaining and aggregate count

Primary hippocampal cultures grown on coverslips were infected at 4 div with titer matched virus (final dilution 104 i.u./ml in neuronal growth media). At 14 div cultures were fixed for 30 min with ice-cold 4% paraformaldehyde and then permeabilized for 30 min with 0.4% saponin in 2% normal donkey serum (NDS). Primary antibody incubations were performed overnight at 4°C using a monoclonal marker of endoplasmic reticulum recognizing endogenous ER-resident proteins containing the KDEL retention signal (KDEL 1:200, Abcam, Cambridge, MA). For detection we used Cy3-conjugated secondary antibodies (Jackson Laboratories, West Grove, PA) in 2% NDS for 1 h at room temperature. Close-up images of neurons were taken on a Leica confocal microscope using a 63X/1.4NA oil objective. The percentage of cells with aggregates was estimated by an unbiased count over multiple fields and coverslips.

Stereotactic injection into the rodent brain

Adult C57BL/6 mice were housed according to the Laboratory Vertebrate Animal protocols at Stanford. All surgeries were performed under aseptic conditions. The animals were anesthetized with intraperitoneal injections of ketamine (80 mg/kg)/xylazine (15–20 mg/kg) cocktail (Sigma). The head was shaved, cleaned with 70% ethanol and betadine and then placed in a stereotactic apparatus (Kopf Instruments, Tujunga, CA; Olympus stereomicroscope). Ophthalmic ointment was applied to prevent eye drying. A midline scalp incision was made and then a small craniotomy was performed using a drill mounted on the stereotactic apparatus (Fine Science Tools, Foster City, CA). The virus was delivered using a 10 μl syringe and a thin 34 gauge metal needle; the injection volume and flow rate (1 μl at 0.1 μl/min) was controlled with an injection pump from World Precision Instruments (Sarasota, FL). After injection the needle was left in place for 10 additional minutes and then slowly withdrawn. The skin was glued back with Vetbond tissue adhesive. The animal was kept on a heating pad until it recovered from anesthetic. Buprenorphine (0.03 mg/kg) was given subcutaneously following the surgical procedure to minimize discomfort. For hippocampal slice imaging: 1 μl of concentrated lentivirus (1010 i.u./ml) carrying NpHR or eNpHR under the CaMKIIα promoter was microinjected into the CA1 region of the left and right adult mouse hippocampus, respectively (anteroposterior, −2.0 mm from bregma; lateral, ±1.5 mm; ventral, 2 mm). For in vivo electrophysiology: 1 μl of eNpHR (1010 i.u./ml) virus was injected in the adult mouse thalamus (anteroposterior −1.8, mm from bregma; lateral, 1.5 mm; ventral, 3.5 mm).

In vivo multiunit recordings

Simultaneous optical stimulation and electrical recording in living mice was done as described previously (Gradinaru et al., 2007) using an optrode composed of an extracellular tungsten electrode (1 MΩ, ~125 μm) tightly attached to an optical fiber (~200 μm, ThorLabs, Newton, NJ) with the tip of the electrode deeper (~0.3 mm) than the tip of the fiber, to ensure illumination of the recorded neurons. The fiberoptic was coupled to a 561 nm laser diode from CrystaLaser (Reno, NV). Single unit recordings were done in animals anesthetized with intraperitoneal injections of ketamine (80 mg/kg)/xylazine (15–20 mg/kg) cocktail (Sigma). pClamp 10 and a Digidata 1322A board (Axon Instruments, Sunnyvale, CA) were used to both collect data and generate light pulses through the fiber. The recorded signal was band pass filtered at 300 Hz low/5 kHz high (1800 Microelectrode AC Amplifier, A-M Systems). For precise placement of the fiber/electrode pair, stereotactic instrumentation (Kopf; Olympus stereomicroscope) was used. Immediately after recordings the animal was sacrificed and brain slices were prepared as described above to check for opsin expression and accurate placement of the optrode.

Notes

Acknowledgments

K.D. is supported by CIRM, McKnight, Coulter, Klingenstein, NSF, NIMH, NIDA, the NIH Pioneer Award, and the Kinetics Foundation. V.G. is supported by a Stanford Graduate Fellowship. K.R.T. is supported by NARSAD. We thank Feng Zhang and Joanna Mattis for providing us with the nhNpHR construct, and Andrew Hsu for assistance with cloning. We also thank the entire Deisseroth lab for useful discussions. The materials and methods described herein are freely distributed and supported by the authors (http://www.stanford.edu/group/dlab).

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

This article is published under an open access license.
Please check the 'Copyright Information' section for details of this license and
what re-use is permitted.
If your intended use exceeds what is permitted by the license or if
you are unable to locate the licence and re-use information,
please contact the Rights and Permissions team.